1. Introduction {#sec0005}
===============

Three species of *Ancylostoma* hookworms, namely *Ancylostoma tubaeforme, Ancylostoma braziliense* and *Ancylostoma ceylanicum*, are common parasites of cats with variable prevalence depending on the geographical region. *Uncinaria stenocephala*, a typical hookworm of canids in temperate regions, has been rarely reported in cats ([@bib0015]). In addition, there are reports on the occurrence in cats of the canine hookworm *A. caninum* ([@bib0005]; [@bib0025]). *Ancylostoma ceylanicum*, unlike the other hookworms infecting cats and dogs, may cause patent infection in humans and therefore impose a remarkable zoonotic risk in endemic areas. It is widespread in subtropical and tropical South East Asia and Pacific region and has also been reported from the Arab Peninsula, southern Africa and South America ([@bib0015]; [@bib0070]).

Like other hookworms, *A. ceylanicum* has a direct life cycle, and infection is acquired by oral ingestion or percutaneous penetration of infective third-stage larvae. The parasitic life cycle of *A. ceylanicum* has been studied in detail in puppies ([@bib0095]): fourth stage larvae were seen within the intestinal wall 2--3 days after oral infection, first immature adults (fifth-stage nematodes) were present in the intestinal lumen as early as 6 days post infection, together with late fourth-stage larvae, and first eggs were passed in the feces 14 days after infection. The development of *A. ceylanicum* in cats has not been studied in detail. However, an early investigation in four kittens until 12 days post infection ([@bib0085]) and recently conducted work determining a pre-patency period of 14--16 days ([@bib0050], [@bib0055]; [@bib0060]) indicate that the development of *A. ceylanicum* in cats is the same as that in dogs.

Prevention and timely treatment of infections with *A. ceylanicum* in companion animals is essential to limit the spread in urban environments and to minimize the risk of transmission to humans of this zoonotic parasite.

Broadline® is a broad spectrum parasiticide which comprises the macrocyclic lactone eprinomectin with nematocidal activity combined with fipronil, (*S*)-methoprene and praziquantel. This topical combination product has been confirmed to be efficacious against various gastrointestinal helminths including adult and developing fourth-stage larval (L4) *A. tubaeforme* and adult *A. braziliense* ([@bib0035]). The high level of efficacy against hookworms was confirmed in a field study conducted in Europe ([@bib0040]).

The study reported here was conducted to evaluate the efficacy of Broadline® in cats against developing L4 and adult *A. ceylanicum* hookworms.

2. Material and methods {#sec0010}
=======================

The study design was based on the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) Guidelines 7 and 20 ([@bib0075], [@bib0080]), and the "World Association for the Advancement of Veterinary Parasitology (WAAVP) guidelines for evaluating the efficacy of anthelmintics for dogs and cats" ([@bib0030]).

The study was conducted in accordance with VICH Guideline 9, entitled *Good Clinical Practice*. Personnel involved in the collection of efficacy data were masked as to the assignment of the cats to treatment groups.

2.1. Experimental animals {#sec0015}
-------------------------

Twenty-four healthy, 22--27 week old purpose-bred European Short Hair cats of equal gender ratio and weighing approximately two to four kg were included in the study. The cats were nematode-naïve and confirmed to be free of patent gastrointestinal nematode infections by standard fecal examination ([@bib0090]) prior to inoculation. Cats were housed individually during the study and fed commercial dry food; the environmental conditions were identical for all animals. Study animals were handled with due regard for their welfare and in compliance with the company's Institutional Animal Care and Use Committee approvals and applicable national regulations.

2.2. Experimental design, inoculation, parasite recovery and count {#sec0020}
------------------------------------------------------------------

For infection, cats were inoculated orally with approximately 300 third-stage larvae of *A. ceylanicum*. The *A. ceylanicum* isolate was of canine origin from Thailand and was maintained in cats in the laboratory for two years prior to use. No vomiting occurred after inoculation of the cats.

Two days post inoculation \[dpi\], the cats were ranked by decreasing pre-treatment body weight, formed into eight blocks of three cats each, and were then allocated randomly to serve either as untreated controls (Group 1) or to receive Broadline® when hookworms were in the developing L4 stage of development (5 dpi; Group 2) or were adults (25 dpi; Group 3). Treatments were administered once topically at the minimum recommended dose of 0.12 mL/kg body weight using disposable 1 mL syringes with 1/100 mL graduation, corresponding to 0.48 to 0.49 mg eprinomectin per kg body weight.

Fecal samples were collected 22 dpi and subjected to a standard McMaster technique ([@bib0090]) for egg counts. For parasite recovery and count, cats were humanely euthanized 35 dpi, and total gastrointestinal tract contents were washed over a 150 μm mesh-sized sieve and examined for nematodes. Morphology of the hookworms recovered was consistent with the descriptions of *A. ceylanicum* by [@bib0010].

2.3. Data analysis {#sec0025}
------------------

*Ancylostoma ceylanicum* counts were transformed to the natural logarithm of (count +1) for calculation of group geometric mean counts. Efficacy was determined by calculating the percent efficacy as 100\[(C-T)/C\], where C was the geometric mean among untreated controls and T was the geometric mean among the treated animals. The log-counts of the treated groups were compared with the log-counts of the control group using a F-test adjusted for the allocation blocks used to randomize the animals to the treatment groups. The mixed procedure in SAS was used for the analysis, with the treatment groups listed as a fixed effect, and the allocation blocks listed as a random effect.

3. Results and discussion {#sec0030}
=========================

Daily observation of the cats throughout the study and hourly observation of the cats for four hours following treatment administration revealed no health problems and no adverse events due to the treatment with Broadline®.

While severe infections of *A. ceylanicum* in dogs have been reported to produce abnormal feces (e. g., loose stool; diarrhea, partly bloody) and anemia ([@bib0020]; [@bib0065]), infections produced from inoculation of approximately 300 *A. ceylanicum* larvae of young, well-nourished cats were, consistent with the observations in the present study, not associated with clinical signs ([@bib0050], [@bib0055]; [@bib0060]).

Experimental studies indicate that the parasitic life cycle of *A. ceylanicum* is the same in both dogs and cats ([@bib0085]; [@bib0095]; [@bib0050], [@bib0055]; [@bib0060]) and allowed to schedule the treatment against developing L4 nematodes in the cats in this study appropriately. However, comparative analysis of data collected in other studies has shown that male and female *A. ceylanicum* recovered from dogs had a larger size than worms recovered from cats but fecundity and number of eggs produced per female worm per day did not differ significantly between dogs and cats ([@bib0045]).

Fecal examination at 22 dpi revealed no eggs in the feces of the cats treated with Broadline® when the hookworms were fourth-stage larvae while all cats of the control group and of the group to be treated when the hookworms were adult passed hookworm eggs (range, 100 to 1000 eggs per gram \[EPG\] and 100--900 EPG, respectively) thus confirming the presence of patent (adult) *A. ceylanicum* infection. The egg counts established were at the lower end of the range of EPG counts reported from other studies where cats were experimentally infected with a similar number of *A. ceylanicum* larvae ([@bib0050], [@bib0055]; [@bib0060]).

Based on worm counts, the efficacy of a single treatment with Broadline® at the minimum label dose was 100% against both developing L4 and adult *A. ceylanicum* (*p* \< 0.001). Thus, treatment with Broadline® of cats when *A. ceylanicum* hookworms were in the developing L4 stage of development or were adult totally eliminated the infectionwhile all cats in the control group were infected (range, 8--35 hookworms; geometric mean count 20.1).

These results are consistent with the level of efficacy of Broadline® treatment found in studies against developing L4 and adult *A. tubaeforme* and adult *A. braziliense* hookworms. The assessment of other products in cats against *A. ceylanicum* was based on fecal egg count reduction only ([@bib0050], [@bib0055]; [@bib0060]) while the present study tested the efficacy of Broadline® based on worm counts after necropsy and thus provide full compliance with the requirements of VICH GL7 and GL20 for the evaluation of the efficacy of anthelmintics in cats. The results of this study demonstrate that Broadline® delivering eprinomectin at the minimum label dose is highly efficacious not only against adult *A. ceylanicum* hookworms but already during the pre-patent phase of infection while the parasites are developing within the host. This is an important feature because it contributes to a more sustainable prevention of hookworm disease by stopping the infection in the cats before becoming patent and in consequence reducing the environmental contamination with hookworm larvae and the risk of transmission of the infection to other animals and humans.

4. Conclusion {#sec0035}
=============

In conclusion, results of this study demonstrate that a single treatment with Broadline® at the minimum recommended dose is effective against developing and adult *A. ceylanicum* infections of cats and qualify Broadline® as highly efficacious and easy-to-apply product to mitigate the risk of human hookworm infections posed by cats.
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